Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,272,704 papers from all fields of science
Search
Sign In
Create Free Account
CB-5083
Known as:
p97 Inhibitor CB-5083
An orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity. Upon oral administration, CB-5083…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Indoles
Pyrimidines
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
L’efficacité in vitro d'un inhibiteur de VCP de première génération (CB-5083) contre le lymphome canin
Alexandra Gareau
2018
Corpus ID: 106111976
2016
2016
Proteasome play C4 debuts
Nature Biotechnology
2016
Corpus ID: 205265923
2016
2016
Abstract 4541: Utilization of K48 poly-ubiquitin modulation as a biomarker of target engagement for a protein homeostasis inhibitor in the clinic: Preclinical validation with CB-5083, a first-in…
M. Menon
,
F. Soriano
,
+15 authors
R. L. Moigne
2016
Corpus ID: 78321494
Background: Pharmacodynamic (PD) biomarkers are an increasingly valuable tool for decision-making and prioritization of lead…
Expand
2015
2015
Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
Daniel J. Anderson
,
R. L. Moigne
,
+15 authors
M. Rolfe
2015
Corpus ID: 79044618
The ubiquitin-proteasome system (UPS) sustains cancer cell viability by alleviating proteotoxic stress caused by an imbalance of…
Expand